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Several lines of evidence support the notion that elevated blood viscosity may predispose to insulin resistance
and type 2 diabetes mellitus by limiting delivery of glucose, insulin, and oxygen to metabolically active tissues. To
test this hypothesis, the authors analyzed longitudinal data on 12,881 initially nondiabetic adults, aged 45–64
years, who were participants in the Atherosclerosis Risk in Communities (ARIC) Study (1987–1998). Whole blood
viscosity was estimated by using a validated formula based on hematocrit and total plasma proteins at baseline. At
baseline, estimated bloodviscosity wasindependently associatedwith several featuresof the metabolic syndrome.
In models adjusted simultaneously for known predictors of diabetes, estimated whole blood viscosity and hemat-
ocrit predicted incident type 2 diabetes mellitus in a graded fashion (Ptrend (linear) < 0.001): Compared with their
counterparts in the lowest quartiles, adults in the highest quartile of blood viscosity (hazard ratio ¼ 1.68, 95%
conﬁdence interval: 1.53, 1.84) and hematocrit (hazard ratio ¼ 1.63, 95% conﬁdence interval: 1.49, 1.79) were over
60% more likely to develop diabetes. Therefore, elevated blood viscosity and hematocrit deserve attention as
emerging risk factors for insulin resistance and type 2 diabetes mellitus.
blood viscosity; diabetes mellitus, type 2; hematocrit; insulin resistance; metabolic syndrome X; oxidative
phosphorylation
Abbreviations: ARIC, Atherosclerosis Risk in Communities; CI, conﬁdence interval; FEV1, forced expiratory volume at 1 second;
RH, relative hazard.
Insulin resistance is a well-established risk factor for type
2 diabetes (1), and improvement of insulin resistance re-
duces this risk (2). The pathophysiology of insulin resis-
tance is complex, and it is thought to involve multiple
derangements in signal transduction in liver, muscle, and
fat (3). Another possible mechanism for insulin resistance
is impaired ﬂow of insulin and glucose to insulin-sensitive
tissues (4–6). Insulin may be unable to increase glucose
uptake if it is not delivered in sufﬁcient quantity because
of decreased microvascular blood ﬂow.
Blood viscosity is inversely related to ﬂow and might
therefore contribute to ﬂow-related insulin resistance (7).
Prior cross-sectional studies have generally supported a link
among elevated blood viscosity, insulin resistance, and type
2 diabetes (8–16). Four prospective studies investigated el-
evated hematocrit, a major determinant of blood viscosity,
as a risk factor for type 2 diabetes (17–20), but these studies
were limited by a suboptimal deﬁnition of diabetes (19, 20)
and selected population samples (17, 18). No population-
based, prospective study has focused on blood viscosity as
a risk factor for insulin resistance or type 2 diabetes.
We therefore analyzed data from the Atherosclerosis Risk
in Communities (ARIC) Study to test the hypothesis that
elevated estimated whole blood viscosity and hematocrit
levels would be cross-sectionally associated with indicators
of insulin resistance and would longitudinally predict the
development of type 2 diabetes mellitus in middle-aged
adults.
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Setting
The ARIC Study is an ongoing, longitudinal cohort study
of atherosclerotic cardiovascular disease in 15,792 adults
aged 45–64 years at baseline. The cohort was selected by
probability sampling from 4 US communities: Forsyth
County, North Carolina; Jackson, Mississippi; the northwest
suburbs of Minneapolis, Minnesota; and Washington
County, Maryland. By design, the Jackson site exclusively
recruited African Americans, thereby accounting for 90% of
African Americans in the study. Most of the remaining
African Americans came from Forsyth County. The sam-
pling procedures and methods used in the ARIC Study have
been described in detail elsewhere (21). Baseline visits were
conducted from 1986 through 1989.
Participants were followed up subsequently by annual
telephone interviews and clinic visits every 3 years. For this
investigation, participants were excluded for the following
reasons: diabetes at baseline (n ¼ 1,870 participants), miss-
ing data (n ¼ 882), extreme hematocrit values (<32%
or >53%, n ¼ 155), and extreme values of total protein
(>9.5 or <5.4 g/dL, n ¼ 4).
Interview and questionnaires
Information on age, sex, race, educational attainment,
cigarette use, physical activity, and parental history of di-
abetes was based on self-report. A positive parental history
of diabetes was deﬁned by participant report of diabetes in
either biologic parent. Parents whose diabetes status could
not be recalled were classiﬁed as nondiabetic. Physical ac-
tivity was assessed by using a modiﬁed version of the ques-
tionnaire developed by Baecke et al. (22). Activity was
classiﬁed as either sports-related (e.g., jogging) or non-
sports-related leisure activity (e.g., gardening) and mea-
sured on a 5-point scale, with ‘‘1’’ indicating the lowest
level of activity and ‘‘5’’ the highest. Cigarette use was
classiﬁed as never, former, or current. Blood pressure was
taken with a random-zero sphygmomanometer, and the
mean of the last 2 of 3 measurements was used. Height
and weight measurements were taken with participants in
scrub suits, and body mass index was calculated (weight
(kg)/height (m)
2). The waist/hip ratio was computed as the
circumference of the waist (umbilical level) divided by that
of the hips (maximum buttocks).
Laboratory evaluation
Participants were asked to fast for at least 12 hours before
morning blood collection. After application of a tourniquet,
blood was drawn from the antecubital vein while partici-
pants were seated. Blood specimens were collected into
vacuum tubes containing serum-separator gel (glucose, in-
sulin, creatinine, and uric acid chemistries) and ethylenedia-
minetetraacetic acid (lipids). Tubes were centrifuged at
3,000 3 g for 10 minutes at 4 C. After separation, aliquots
were quickly frozen at  70 C until analysis was performed
(within a few weeks). Serum glucose was assessed by a
modiﬁed hexokinase/glucose-6-phosphate dehydrogenase
procedure. A standard radioimmunoassay was used to de-
termine the serum insulin level. Triglycerides (23) were
measured by enzymatic methods, high density lipoprotein
cholesterol (24) was measured after dextran-magnesium
precipitation, and low density lipoprotein cholesterol
was calculated by using the equation of Friedewald et al.
(25). Insulin resistance was estimated by using homeostasis
model assessment (26). The hematocrit level was cal-
culated from the measurement of red blood cells and
either the calculated erythrocyte mean cell volume (Coulter
counter; Coulter Diagnostics, Hialeah, Florida) or pattern
of light scattering (Hemalog H-6000; Technicon Corpora-
tion, Tarrytown, New York). To measure total proteins,
we used the DART total protein reagent (Coulter no.
7546061; Coulter Diagnostics) that incorporates a modiﬁed
Gornall method (27). Serum creatinine and ﬁbrinogen
were measured as described previously (28). White blood
cell counts were determined by Coulter counters in hospital
laboratories inthe 4communities. Forcedexpiratoryvolume
at 1 second (FEV1) was assessed by spirometry (29).
Estimation of whole blood viscosity
Whole blood viscosity at 208 seconds
 1 of shear stress
was estimated by a previously validated formula (30) that
takes into account hematocrit and plasma proteins:
Whole blood viscosity

208seconds 1
¼½ 0:123h þ½ 0:173ðp   2:07Þ ;
where h is hematocrit (%) and p is plasma protein concen-
tration (g/dL). The unit for viscosity is the centipoise (cP)
corresponding to the ratio of the shear rate of blood to the
shear rate of water. The formula has been validated in
healthy adults through a range of hematocrit (32%–53%)
and plasma protein concentration (5.4–9.5 g/dL) and per-
mits the estimation of blood viscosity in studies where the
direct measurement is not feasible (8, 30, 31). We selected
a high level of shear stress (208 seconds
 1) for 2 reasons:
First, the correlation between estimated and actual viscosity
is strongest at high levels (30), and second, high levels of
shear stress correspond best to the hemodynamics in arteri-
oles and precapillary vessels where viscosity is most likely
to inﬂuence ﬂow (32).
To conﬁrm the robustness of our results, we also con-
ducted subsidiary analysis by using a validated variation
of the formula that corresponds to a lower shear stress
(0.5 second
 1) (30):
Whole blood viscosity

0:5second 1
¼½ 1:893h þ½ 3:763ðp   78:42Þ :
The risk relations that we observed by using the low shear
stress formula were virtually identical to those obtained by
the high shear stress formula. For brevity, we show only the
former.
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Individuals were classiﬁed as having diabetes mellitus if
any of the following conditions, adapted from 1997
American Diabetes Association criteria (33), were met: fast-
ingserumglucoselevelsofatleast7.0mmol/L(126mg/dL),
nonfasting glucose levels of at least 11.1 mmol/L (200 mg/
dL), current use of medications prescribed to treat diabetes
(e.g., insulin or sulfonylureas), or a positive response to the
question, ‘‘Has a doctor ever told you that you had diabetes
(sugar in the blood)?’’; 98% of the diagnoses were based on
fasting glucose levels. Results were unchanged after ex-
cluding the 2% classiﬁed according to nonfasting glucose.
For this study, individuals with diabetes at baseline were
excluded. Individuals without diabetes at baseline who sub-
sequently met any of these criteria at visits 2, 3, or 4 were
considered to have incident diabetes. All incident cases of
diabeteswere classiﬁedastype 2,becausethe ageofonset in
the ARIC Study cohort was between 45 and 73 years.
Statistical analysis
In cross-sectional analysis, baseline characteristics of the
study population were examined by gender-speciﬁc esti-
mated whole blood viscosity quartiles by using linear re-
gression. We then used multiple linear regression to estimate
the association between quartiles of estimated whole blood
viscosity and features of insulin resistance. Spearman’s cor-
relations were calculated to examine the relation among
estimated blood viscosity, hematocrit, and plasma proteins.
Incidence rates of diabetes were calculated for each quar-
tile of whole blood viscosity by using a person-years ap-
proach. For participants without diabetes, person-years were
calculated from baseline to the last visit date. Poisson re-
gression was used to calculate 95% conﬁdence intervals and
to adjust for age, sex, and race. In the time-to-event analy-
ses, we used interval censoring to reduce bias (34). To
estimate the relative risk of developing type 2 diabetes as-
sociated with quartiles of estimated whole blood viscosity,
we used accelerated failure time models assuming a Weibull
distribution (35). Accelerated failure time models are para-
metric regression methods able to handle interval censoring
(34). We chose interval censoring rather than event censor-
ing because we did not know the exact day when diabetes
started but, rather, when it was discovered at the ARIC
Study research visit. We also assessed the individual con-
tributions of hematocrit and plasma protein levels to the risk
of incident type 2 diabetes and used standardized coefﬁ-
cients to facilitate comparisons with whole blood viscosity-
related risk.
Analyses were performed by using SAS, version 8.1,
software (SAS Institute, Inc., Cary, North Carolina), and
all signiﬁcance tests were 2 tailed.
RESULTS
Baseline characteristics
Selected baseline characteristics of the cohort of 12,881
middle-aged adults are shown by quartiles of estimated
whole blood viscosity in Table 1. Estimated whole blood
viscosity was higher in whites and smokers and was posi-
tively associated with higher body mass index, waist cir-
cumference, waist/hip ratio, systolic blood pressure,
Table 1. Baseline Characteristics of 12,881 Middle-aged Adults Without Diabetes by Quartile of Estimated Whole Blood Viscosity at Baseline,
Atherosclerosis Risk in Communities Study, 1987–1998
a
Characteristic
Estimated Whole Blood Viscosity
Ptrend Quartile 1, <3.8 cP
(N 5 3,224)
Quartile 2, 3.8–4.1 cP
(N 5 3,229)
Quartile 3, 4.2–4.4
cP (N 5 3,209)
Quartile 4, >4.4 cP
(N 5 3,219)
Age, years 53.1 (5.7) 54.1 (5.7) 54.4 (5.7) 54.2 (5.6) <0.001
Female, % 92 75 40 13 <0.001
Black, % 32 23 20 18 <0.001
Education <11 years, % 19 21 22 23 0.011
Body mass index, kg/m
2 26.8 (5.6) 27 (5.2) 27.3 (4.9) 27.6 (4.4) <0.001
Waist circumference, cm 92.3 (14.3) 94.2 (13.7) 97.0 (12.8) 99.4 (11.5) <0.001
Waist/hip ratio 0.87 (0.07) 0.90 (0.07) 0.93 (0.06) 0.96 (0.06) <0.001
Physical activity, points (1, lowest; 5, highest) 2.39 (0.58) 2.41 (0.58) 2.39 (0.55) 2.33 (0.53) <0.001
Glucose, mg/dL 96.1 (8.6) 97.6 (9.2) 99.6 (9.1) 101.1 (9.3) <0.001
Insulin, pmol/L 66.3 (50.4) 74.2 (57.6) 78.4 (58.5) 90.0 (61.3) <0.001
High density lipoprotein cholesterol, mg/dL 60.2 (17.3) 56 (17.2) 49.7 (15.6) 44.8 (13.7) <0.001
Triglycerides, mg/dL 103.4 (52.3) 114.7 (56.7) 125.4 (62.4) 137.8 (66.3) <0.001
Systolic blood pressure, mm Hg 117.5 (18.5) 119.0 (18.2) 120.8 (17.4) 121.8 (17.0) <0.001
FEV1, L 2.5 (0.5) 2.6 (0.6) 2.9 (0.8) 3.1 (0.8) <0.001
Current smokers, % 16 26 28 34 <0.001
Abbreviations: cP, centipoise; FEV1, forced expiratory volume at 1 second.
a Results are shown as mean (standard deviation) or percentage.
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triglyceride levels, but it was inversely associated with high
density lipoprotein cholesterol levels (all Ptrend (linear) <
0.001).
Estimated whole blood viscosity remained associated
with features of the metabolic syndrome after multivariate
adjustment (Table 2). In multivariate linear regression mod-
els that included age, sex, race, body mass index, center,
parental history of diabetes, physical activity, waist/hip ra-
tio, and current smoking status, estimated whole blood vis-
cosity showed graded associations with higher baseline
blood pressure, estimated insulin resistance, fasting glucose
and triglyceride levels, and lower high density lipoprotein
cholesterol (all Ptrend (linear) < 0.001).
As expected, whole blood viscosity was more strongly
correlated with hematocrit (r ¼ 0.986, P < 0.01) than with
plasma proteins (r ¼ 0.15, P < 0.01). In contrast, there was
no association between hematocrit and plasma proteins (r ¼
0.007, P ¼ 0.374).
Incident type 2 diabetes mellitus
Over 9 years of follow-up, 1,392 people developed type 2
diabetes. Diabetes was positively associated with greater
estimated whole blood viscosity, rising from 11.2 per
1,000 person-years in the lowest quartile of estimated blood
viscosity to 20 per 1,000 person-years in the highest quar-
tile. This nearly 2-fold gradient persisted after adjustment
for age, sex, and race.
Multivariate analysis
To further examine the association of estimated whole
blood viscosity to incident diabetes risk independent of po-
tential confounders, we used accelerated failure time mod-
els (Figure 1). After simultaneous adjustment for age, sex,
race, parental history of diabetes, education, ﬁeld center,
body mass index, waist/hip ratio, smoking, and physical
activity, there was a strong, graded relation of estimated
whole blood viscosity to the subsequent risk of incident type
2 diabetes (relative hazard (RH) ¼ 1.68, 95% conﬁdence
interval (CI): 1.53, 1.84) in the highest quartile of estimated
whole blood viscosity. Similar risk gradients were found for
hematocrit and plasma protein, with relative hazards of 1.63
(95% CI: 1.49, 1.74) and 1.25 (95% CI: 1.17, 1.35), respec-
tively, in the highest quartiles.
We further examined the relation between whole blood
viscosity, hematocrit, and plasma protein and incident
diabetes after adjustment for other potential mediators
(Table 3). These risk relations remained virtually identical
after adjustment for body mass index (model B), insulin
resistance (homeostasis model assessment of insulin resis-
tance; model C), and factors related to hematocrit (FEV1,
blood urea nitrogen/creatinine ratio) and plasma proteins
(white blood cells and ﬁbrinogen; model D). Although the
relations remained signiﬁcant in most cases, full adjustment
attenuated the associations (model E) (Table 3).
Assessment of interaction
No signiﬁcant interactions were identiﬁed. Estimated
blood viscosity predicted incident diabetes in both men
(per 1-standard deviation difference: RH ¼ 1.15, 95% CI:
1.04, 1.26) and women (per 1-standard deviation difference:
RH ¼ 1.14, 95% CI: 1.04, 1.26) after adjustment for age,
ethnicity, ﬁeld center, family history of diabetes, educa-
tional level, body mass index, waist/hip ratio, smoking his-
tory, FEV1, blood urea nitrogen/creatinine ratio, systolic
blood pressure, physical activity, white blood cells, and ﬁ-
brinogen. Blood viscosity predicted incident diabetes simi-
larly in whites and African Americans (Pinteraction ¼ 0.35)
and in smokers and nonsmokers (Pinteraction ¼ 0.72).
DISCUSSION
These data suggest that elevated levels of hematocrit and
whole blood viscosity are associated with insulin resistance
and are independent predictors of type 2 diabetes. These
relations were graded and independent of a wide range of
established type 2 diabetes risk factors. Strengths of the
study that lend weight to these conclusions are its prospec-
tive design, large community-based sample, and carefully
standardized assessments.
Nonetheless, several limitations deserve mention. First,
we had no direct measurement of blood viscosity. Our esti-
mates, however, were based on a prediction equation that
has been validated in 3 prior studies (8, 30, 31). Second, we
Table2. SelectedFeaturesRelatedto MetabolicSyndromeat Baseline byQuartilesof Estimated WholeBloodViscosity, Atherosclerosis Riskin
Communities Study, 1987–1998
a
Quartile Systolic Blood
Pressure, mm Hg
Diastolic Blood
Pressure, mm Hg
HDL-c,
mg/dL
Triglyceride
Level, mg/dL
Fasting
Glucose, mg/dL
Fasting
Insulin, pmol/L HOMA-IR
1 117.9 (0.29) 70.9 (0.17) 54.3 (0.25) 110.1 (1.00) 97.2 (0.15) 64.0 (0.85) 39.4 (0.58)
2 119.1 (0.16) 72.5 (0.10) 53.2 (0.14) 116.9 (0.57) 98.1 (0.08) 72.8 (0.49) 45.4 (0.33)
3 120.4 (0.16) 74.1 (0.10) 52.2 (0.14) 123.7 (0.57) 99.1 (0.08) 81.6 (0.49) 51.3 (0.33)
4 121.7 (0.29) 75.7 (0.17) 51.1 (0.25) 130.5 (1.00) 100.0 (0.15) 90.4 (0.85) 57.3 (0.58)
Ptrend <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Abbreviations: HDL-c, high density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance deﬁned as (fasting
plasma insulin (lU/mL) 3 fasting plasma glucose (mmol/L))/22.5.
a Results are presented as the adjusted mean (standard error) for multivariate linear regression models that included age, gender, center, race,
body mass index, waist/hip ratio, current smoking, parental history of diabetes, and physical activity.
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cosity, such as erythrocyte rigidity and aggregability. How-
ever, whole blood viscosity is largely determined by
hematocrit and plasma protein levels (36). Finally, the high
correlation between hematocrit and estimated blood viscos-
ity precluded investigating whether hematocrit could medi-
ate the risk of diabetes by mechanisms other than through
increases in blood viscosity.
Since 1965, there have been 10 cross-sectional studies
(8–16, 31) of rheologic parameters related to insulin resis-
tance. Eight smaller studies found that high levels of whole
blood viscosity were associated with insulin resistance mea-
sured by euglycemic hyperinsulinemic clamp (8, 10–12,
14–16, 31). Two larger studies found an association between
high whole blood viscosity and markers of insulin resistance
(9, 13). These studies were limited by small sample sizes
and cross-sectional designs.
No previous study has examined the association of vis-
cosity with the risk of type 2 diabetes. However, 4 published
studies (17–20) reported a prospective association between
hemoglobin or hematocrit and the subsequent occurrence of
type 2 diabetes. In British men, Wannamethee et al. (17)
found that hematocrit had a strong, graded relation to in-
cident type 2 diabetes after 12 years of follow-up, but the
study was limited by reliance on self-report for outcome
assessment. Medalie et al. (19) found an association in mid-
dle-aged adults between hemoglobin and incident diabetes
in 8,688 Israeli government and municipal workers aged 40
years or older. In a sample of 5,082 middle-aged adults in
the Framingham Heart Study, hemoglobin predicted glucose
intolerance among women only (20). Both studies used an
olderdeﬁnitionofdiabetes.Recently,Tulloch-Reidetal.(18)
found that hematocrit was associated with incident type 2
diabetes among 1,286 Pima Indians followed over 11 years.
After adjustment for fasting insulin in a subset, however,
hematocritwasnolongerassociatedwithdiabetes.Ourstudy
conﬁrms the relation between hemoglobin or hematocrit and
subsequent development of type 2 diabetes in a population-
based, middle-aged cohort including men and women. Fur-
thermore, our ﬁnding that plasma proteins and calculated
viscosity also predict incident type 2 diabetes suggests that
a higher level of hematocrit leads to type 2 diabetes through
its effect on viscosity and, therefore, blood ﬂow.
According to Poiseuille’s law (37), the rate of blood ﬂow
(Q) may be calculated from the following formula:
Q ¼

p3DP3r4
ð83g3LÞ;
where D P is the blood pressure difference between the ends
of the vessel, r is the radius of the vessel, g is whole blood
viscosity, and L is the length of the vessel. Holding other
factors constant, higher blood viscosity should therefore de-
crease ﬂow (38). Decreased blood ﬂow, in turn, decreases
the delivery of substrate such as insulin, glucose, and oxy-
gen to skeletal muscle (4, 5). Compensatory mechanisms to
increase blood ﬂow would include vasodilatation and blood
pressure elevation (38–40). Once these mechanisms are
maximized, elevations in glucose and insulin would be re-
quired to further increase their delivery (ﬂow 3 concentra-
tion) to muscle (6). Therefore, an increase in viscosity is
a sufﬁcient cause of increased glucose and insulin when
other compensatory mechanisms are not sufﬁcient to main-
tain blood ﬂow at optimal levels.
Increased blood viscosity may contribute to insulin re-
sistance through an additional mechanism. Accumulating
evidence implicates insufﬁcient oxidative capacity in mus-
cle as a primary cause of insulin resistance. This evidence
includes the association of insulin resistance and type 2
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Figure 1. Adjustedrelative hazardsand 95% conﬁdence intervalsof
incident type 2 diabetes by quartiles of estimated whole blood viscos-
ity (A), hematocrit (B), and plasma proteins (C), Atherosclerosis Risk
in Communities Study, 1987–1998. All relative hazards were adjusted
for age, sex, race, family history, education, center, body mass index,
waist/hip ratio, smoking history, and physical activity. cP, centipoise.
Ptrend: <0.01 (A), <0.01 (B), and 0.01 (C).
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drial dysfunction (41–46), decreased mitochondrial size and
density (43, 47, 48), decreased oxidative gene expression
(47, 49–51), decreased oxidative phosphorylation (52–57),
and decreased whole body aerobic capacity (49, 58, 59).
Increased blood viscosity may also limit oxidative capacity
throughdecreasedoxygendelivery.Inthe settingofincreased
viscosity, the concentration of glucose and insulin can in-
crease, returning their delivery to normal. Oxygen delivery,
however, can not increase, because an increased hemoglobin
concentration would further increase viscosity. Therefore,
compensatory mechanisms are unable to fully restore oxygen
delivery, limiting oxidative capacity and promoting insulin
resistance. Alternatively, increased hematocrit levels and,
therefore, increased viscosity may be a compensatory re-
sponsetoa primarydecreaseinoxidative capacity. Thelongi-
tudinal association of viscosity with type 2 diabetes in this
work makes this possibility less likely, however.
Other lines of evidence support the role of decreased sub-
strate delivery in insulin resistance. Several investigators
have shown that people at high risk of developing type 2
diabetes have impaired microvascular function. Further-
more, recent epidemiologic studies have implicated nar-
rowed arterioles and endothelial dysfunction (60, 61) and
higher blood pressure (61) as antecedents of type 2 diabetes.
Finally, in randomized controlled trials, angiotensin-
converting enzyme inhibitors reduce the risk of developing
type 2 diabetes among high-risk persons (62, 63). This effect
maybemediatedthroughimprovedmicrovascularbloodﬂow.
If our hypothesis is correct, then the risk of type 2 di-
abetes associated with elevated levels of hematocrit (17–20)
and plasma protein (64), high altitude (65, 66), pulmonary
disease (67, 68), and elevated circulating levels of inﬂam-
matory factors could be mediated, in part, by their effect on
blood viscosity. Several factors that affect hematocrit have
been already found to be associated with type 2 diabetes.
Smoking (69, 70), pulmonary disease (67, 68), and acute
ascent to high altitude (65, 66) have been shown to induce
glucose intolerance or to predict type 2 diabetes mellitus.
Moreover, oral glucose tolerance improves after phlebot-
omy in healthy individuals (71, 72). Serum immunoglobu-
lins, white blood cell count, and various acute-phase
reactants all predict diabetes (64, 73, 74) while contributing
to blood viscosity (37). However, in our study, the effect of
viscosity on the risk of diabetes was minimally affected by
adjustment for inﬂammatory markers.
The main implication of our study is that elevated blood
viscosity might be an independent risk factor for type 2
diabetes. This work supports the hypothesis that decreased
delivery of substrate leads to the development of insulin re-
sistance and type 2 diabetes. It would also suggest that high
viscosity is a potential mediator, at least in part, for a variety
of emerging diabetes risk factors that affect hematocrit (e.g.,
hypoxemia), plasma proteins (e.g., inﬂammation), or both
(e.g., cigarette smoking). Whether modiﬁcation of blood
viscosity might inﬂuence diabetes risk awaits further study.
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Table 3. Adjusted, Standardized Relative Hazards of Incident Type 2 Diabetes Related to Estimated Whole Blood Viscosity, Hematocrit, and
Plasma Proteins, Atherosclerosis Risk in Communities Study, 1987–1998
a
Risk Factor
Whole Blood Viscosity Hematocrit Plasma Proteins
RH
b 95% Conﬁdence
Interval P Value RH
b 95% Conﬁdence
Interval P Value RH
b 95% Conﬁdence
Interval P Value
Model A 1.34 1.25, 1.43 <0.01 1.32 1.23, 1.41 <0.01 1.14 1.08, 1.20 <0.01
Model B 1.23 1.15, 1.32 <0.01 1.21 1.13, 1.30 <0.01 1.11 1.05, 1.18 <0.01
Model C 1.21 1.13, 1.29 <0.01 1.20 1.12, 1.28 <0.01 1.07 1.01, 1.13 <0.01
Model D 1.20 1.13, 1.29 <0.01 1.19 1.11, 1.27 <0.01 1.11 1.05, 1.18 <0.01
Model E 1.11 1.04, 1.19 0.001 1.11 1.03, 1.19 0.003 1.05 0.99, 1.11 0.06
Abbreviations: BUN, blood urea nitrogen; FEV1, forced expiratory volume at 1 second; HOMA-IR, homeostasis model assessment of insulin
resistance deﬁned as (fasting plasma insulin (lU/mL) 3 fasting plasma glucose (mmol/L))/22.5; RH, relative hazard; SD, standard deviation; WBC,
white blood cell count.
a Model A adjusts simultaneously for age, sex, race, and ﬁeld center. Model B adjusts simultaneously for all variables in model A as well as body
mass index. Model C adjusts simultaneously for all variables in model A as well as HOMA-IR. Model D adjusts simultaneously for all variables in
model B as well as smoking, number of cigarettes per year in current smokers, FEV1, BUN/creatinine ratio, physical activity, WBC, and ﬁbrinogen.
Model E adjusts simultaneously for all variables in model D as well as HOMA-IR.
b RH indicates adjusted relative hazards per 1-standard deviation difference in whole blood viscosity (SD ¼ 0.453), hematocrit (SD ¼ 3.72), and
plasma protein (SD ¼ 0.44).
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